Status:

COMPLETED

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Lead Sponsor:

Alkermes, Inc.

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.

Eligibility Criteria

Inclusion

  • Has a diagnosis of schizophrenia
  • Requires acute treatment for symptoms of schizophrenia
  • Willing and able to be confined to an inpatient study unit for up to 3-4 weeks
  • Has experienced at least one previous hospitalization for schizophrenia
  • Has been able to achieve outpatient status for more than 3 months in the past year
  • Has a body mass index (BMI) between 18.0 and 40.0 kg/m\^2
  • Resides in a stable living situation when not hospitalized
  • Has an identified reliable caregiver (for example, family member)
  • Additional criteria may apply

Exclusion

  • Poses a current suicide risk
  • Pregnant, planning to become pregnant, or breastfeeding
  • Initiated first antipsychotic treatment within the past 12 months
  • Has received a long-acting injectable antipsychotic in the past 3 months
  • Has participated in a clinical study involving any investigational product within the past 3 months, or is currently participating in a clinical study involving an investigational product.
  • A positive urine drug test for drugs of abuse
  • Additional criteria may apply

Key Trial Info

Start Date :

November 15 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 12 2019

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03345979

Start Date

November 15 2017

End Date

March 12 2019

Last Update

August 11 2020

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Alkermes Investigational Site

Little Rock, Arkansas, United States, 72211

2

Alkermes Investigational Site

Rogers, Arkansas, United States, 72758

3

Alkermes Investigational Site

Cerritos, California, United States, 90703

4

Alkermes Investigational Site

Culver City, California, United States, 90230